Investment Rating - The investment rating for the company is "Buy" and maintained [1] Core Views - The company is expected to achieve total operating revenue of 11.546 billion yuan, a year-on-year increase of 14.31%, with a net profit attributable to shareholders of 3.412 billion yuan, reflecting an 8.8% growth [3] - The company's gross margin is projected to be 74.75%, with a net profit margin of 29.55%, showing a slight decline compared to the previous year [3] - The company aims for a revenue growth of 5%-12% in 2025, with net profit growth slightly lower than revenue growth [10] Company Overview - The latest closing price is 47.40 yuan, with a total market capitalization of 59.1 billion yuan [2] - The company has a total share capital of 1.247 billion shares, with a debt-to-asset ratio of 36.2% and a price-to-earnings ratio of 17.32 [2] Financial Performance - In Q4 2024, the company reported total operating revenue of 1.604 billion yuan, a decrease of 7.56% year-on-year, with a net profit of 326 million yuan, down 34.84% [4] - For Q1 2025, the company achieved total operating revenue of 509.9 million yuan, reflecting a year-on-year increase of 9.17% [6] - The company’s revenue from direct sales and wholesale in 2024 was 2.73 billion yuan and 11.205 billion yuan, respectively, showing growth of 20.78% and 14.19% [5] Revenue Breakdown - In 2024, the revenue from different product categories was as follows: Special A+ 749.1 million yuan, Special A 334.7 million yuan, A class 41.9 million yuan, B class 14.2 million yuan, and CD class 7.4 million yuan, with year-on-year growth rates of 15.17%, 16.61%, 1.95%, -11.09%, and -14.57% respectively [5] - Revenue from various regions in 2024 included: Huai'an 2.235 billion yuan, Nanjing 2.631 billion yuan, and other regions showing strong growth [5] Earnings Forecast - The company forecasts operating revenues of 12.704 billion yuan, 13.994 billion yuan, and 16.118 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 3.696 billion yuan, 4.109 billion yuan, and 4.863 billion yuan [12][10] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 2.96 yuan, 3.30 yuan, and 3.90 yuan, respectively [12]

Investment Rating - The investment rating for the company is "Buy" and is maintained [2][10]. Core Views - The company's performance in 2024 exceeded expectations, with significant improvements in cost control [5][10]. - The company is expected to continue its growth trajectory, driven by the introduction of new products and channel expansion [8][10]. Company Overview - Latest closing price: 43.12 CNY - Total shares: 1.69 billion, circulating shares: 1.14 billion - Total market capitalization: 73 billion CNY, circulating market capitalization: 49 billion CNY - 52-week high/low: 47.99 CNY / 22.58 CNY - Debt-to-asset ratio: 41.2% - Price-to-earnings ratio: 27.04 [4]. Financial Performance - In 2024, the company achieved revenue of 3.835 billion CNY, net profit attributable to shareholders of 268 million CNY, and adjusted net profit of 254 million CNY, representing year-on-year growth of 9.61%, 266.94%, and 108.22% respectively [5]. - For Q4 2024, revenue was 1.118 billion CNY, net profit was 65 million CNY, and adjusted net profit was 62 million CNY, with year-on-year growth of 21.99%, 175.96%, and 359.73% respectively [5]. - In Q1 2025, revenue reached 1.046 billion CNY, net profit was 88 million CNY, and adjusted net profit was 86 million CNY, showing year-on-year growth of 14.13%, 15.11%, and 27.3% respectively [5]. Revenue Growth Drivers - The growth in 2024 was primarily driven by high growth in cream products, leading to double-digit growth in distribution channels, while supermarket channels experienced a decline due to product cycle adjustments [6]. - In Q1 2025, the company saw strong performance from new products in Sam's Club, with supermarket channel revenue growing over 40% due to the launch of core customer new products [6]. Cost Control and Profitability - The company achieved a gross margin of 31.47% and a net margin of 6.99% in 2024, with significant improvements in expense ratios [7]. - For Q1 2025, the gross margin was 29.99% and the net margin was 8.45%, maintaining stability despite cost pressures from rising raw material prices [7]. Future Outlook - The company plans to deepen its cream product strategy and continuously launch customized new products to drive revenue growth from both product and channel perspectives [8]. - The company is also addressing capacity constraints by investing in new production lines for cream products [8][9]. Earnings Forecast - Revenue forecasts for 2025 and 2026 have been adjusted to 4.466 billion CNY and 5.049 billion CNY, respectively, with year-on-year growth of 16.45% and 13.05% [10]. - Net profit forecasts for 2025 and 2026 have been adjusted to 357 million CNY and 414 million CNY, respectively, with year-on-year growth of 33.24% and 15.93% [10].

Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Views - The company has shown significant profit growth in Q1 2024, with a notable increase in net profit by 271.83% year-on-year, primarily due to a substantial reduction in financial expenses [5] - The company is focusing on enhancing its AI capabilities and has established a comprehensive AI-driven model to support financial institutions in overcoming challenges related to data security and compliance [6] - The collaboration with Alibaba has strengthened the company's position in the fintech sector, leading to the launch of 57 financial intelligent solutions [7][8] - The company is actively expanding its new business segments, achieving a total contract amount exceeding 8.1 billion yuan in 2024, with a focus on digital agriculture and smart energy [9] - The future outlook for the company is positive, with projected EPS of 0.37, 0.45, and 0.52 yuan for 2025-2027, indicating a favorable growth trajectory [10] Company Overview - The latest closing price of the company is 13.15 yuan, with a total market capitalization of 77 billion yuan [4] - The company has a total share capital of 5.85 billion shares, with 5.49 billion shares in circulation [4] - The company has a debt-to-asset ratio of 29.1% and a current P/E ratio of 62.62 [4] Financial Performance - In 2024, the company reported total revenue of 68.99 billion yuan, a decrease of 4.50% year-on-year, while the net profit attributable to the parent company was 1.24 billion yuan, down 42.81% [5] - The projected revenue for 2025 is 74.75 billion yuan, with an expected growth rate of 8.35% [12] - The company anticipates a significant recovery in net profit, with projections of 218 million yuan in 2025, reflecting a growth rate of 75.42% [12]

资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 13.15 | | --- | --- | | 总股本/流通股本（亿股）5.85 / 5.49 | | | 总市值/流通市值（亿元）77 / 72 | | | 52 周内最高/最低价 | 16.94 / 7.32 | | 资产负债率(%) | 29.1% | | 市盈率 | 62.62 | | 第一大股东 | 王斌 | 证券研究报告：计算机 | 公司点评报告 发布时间：2025-05-06 股票投资评级 买入|维持 个股表现 -23% -13% -3% 7% 17% 27% 37% 47% 57% 67% 77% 2024-04 2024-07 2024-09 2024-12 2025-02 2025-04 博彦科技 计算机 "技术+场景+生态"，AI 驱动效率革命 研究所 分析师:孙业亮 SAC 登记编号:S1340522110002 Email:sunyeliang@cnpsec.com 分析师:丁子惠 SAC 登记编号:S1340523070003 Email:dingzihui@cnpsec.com AI 大模型在金融业的规模化应 ...

Investment Rating - The investment rating for the company is "Buy" and maintained [2][10]. Core Insights - The company's performance in 2024 exceeded expectations, with significant improvements in cost control leading to a notable increase in net profit [5][7]. - The company is focusing on a single product strategy for cream and plans to introduce customized new products to drive revenue growth [8][9]. - The company is facing some cost pressures due to rising raw material prices but is managing to maintain stable profit margins through effective cost control measures [9]. Company Overview - The latest closing price is 43.12 CNY, with a total market capitalization of 73 billion CNY and a circulating market value of 49 billion CNY [4]. - The company has a total share capital of 1.69 billion shares, with 1.14 billion shares in circulation [4]. - The company's debt-to-asset ratio stands at 41.2%, and the price-to-earnings ratio is 27.04 [4]. Financial Performance - In 2024, the company achieved operating revenue of 3.835 billion CNY, a year-on-year increase of 9.61%, and a net profit attributable to shareholders of 268 million CNY, up 266.94% [5][12]. - For Q1 2025, the company reported operating revenue of 1.046 billion CNY, a 14.13% increase year-on-year, and a net profit of 88 million CNY, reflecting a 15.11% growth [5][12]. - The company expects to continue revenue growth in 2025, with projected operating revenues of 4.466 billion CNY and net profits of 357 million CNY, representing year-on-year increases of 16.45% and 33.24%, respectively [10][12]. Product and Channel Performance - In 2024, the cream product line drove double-digit growth in distribution channels, while the supermarket channel experienced a decline due to product cycle adjustments [6]. - In Q1 2025, the supermarket channel showed a recovery with over 40% year-on-year revenue growth, primarily due to the launch of new products for key customers [6][8]. - The company plans to enhance its product offerings in the frozen baking segment with new ice cream cakes and other upgraded products [8]. Cost Management - The company has implemented strict control over its headquarters personnel and sales incentive mechanisms, leading to significant optimization of expense ratios [7]. - Despite facing cost pressures from rising raw material prices, the company has managed to maintain stable profit margins through effective cost management strategies [9]. Earnings Forecast - The earnings forecast for 2025-2026 has been adjusted to reflect higher expected revenues and profits, with projected revenues of 4.466 billion CNY and 5.049 billion CNY for 2025 and 2026, respectively [10][12]. - The expected earnings per share (EPS) for 2025 and 2026 are projected to be 2.11 CNY and 2.44 CNY, respectively, with corresponding price-to-earnings ratios of 20.90 and 18.03 [10][12].

Industry Investment Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Views - The report highlights that the precious metals market is experiencing fluctuations, with gold and silver showing volatility after the April non-farm payroll data exceeded expectations. The easing of tariff expectations and the appreciation of the offshore RMB may exert pressure on gold prices [4] - Copper prices are expected to oscillate around $9,300 due to intertwined trade and macro pricing dynamics, with recent tariff expectations improving market sentiment [5] - Aluminum prices may continue to rise in the short term due to strong domestic demand, but potential weakness is anticipated starting in the second half of 2025 [5] - Antimony prices are expected to remain high due to supply constraints, while tin prices are under pressure from anticipated restarts in Myanmar and the Democratic Republic of the Congo [6] Summary by Sections 1. Market Performance - The non-ferrous metals sector experienced a weekly decline of 0.7%, ranking 20th among sectors [13] 2. Prices - Basic metals saw slight declines: LME copper down 0.04%, aluminum down 0.14%, zinc down 1.15%, lead down 0.69%, and tin down 3.42%. Precious metals also faced declines, with COMEX gold down 2.49% and silver down 2.54% [18] 3. Inventory - Global visible inventories showed a decrease: copper down 2,489 tons, aluminum down 8,027 tons, zinc down 4,552 tons, lead down 4,721 tons, tin down 267 tons, and nickel down 432 tons [24]

Industry Investment Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Views - The report highlights that the precious metals market is experiencing fluctuations, with gold and silver showing volatility after the April non-farm payroll data exceeded expectations. The easing of tariff expectations and the appreciation of the offshore RMB may exert pressure on gold prices [4] - Copper prices are expected to oscillate around $9,300 due to intertwined trade and macro pricing dynamics, with recent tariff expectations improving market sentiment [5] - Aluminum prices may continue to rise in the short term due to strong domestic demand, but potential weakness is anticipated starting in the second half of 2025 [5] - Antimony prices are expected to remain high due to supply constraints, while tin prices are under pressure from anticipated restarts in Myanmar and the Democratic Republic of the Congo [6] Summary by Sections Industry Overview - The closing index for the industry is at 4603.44, with a weekly high of 5020.22 and a low of 3700.9 [1] Price Movements - Basic metals saw slight declines: LME copper down 0.04%, aluminum down 0.14%, zinc down 1.15%, lead down 0.69%, and tin down 3.42%. Precious metals also experienced declines, with COMEX gold down 2.49% and silver down 2.54% [18] Inventory Changes - Global visible inventories showed a decrease: copper down 2489 tons, aluminum down 8027 tons, zinc down 4552 tons, lead down 4721 tons, tin down 267 tons, and nickel down 432 tons [24]

发布时间：2025-04-30 研究所 分析师:肖承志 SAC 登记编号:S1340524090001 Email:xiaochengzhi@cnpsec.com 近期研究报告 《年报效应边际递减，右侧买入信号 触发——微盘股指数周报 20250427》 - 2025.04.27 《动量波动分化，低波高涨占优—— 中邮因子周报 20250427》 - 2025.04.27 《OpenAI 发布 GPT-4.1，智谱发布 证券研究报告：金融工程报告 GLM-4-32B-0414 系列——AI 动态汇总 20250421》 - 2025.04.23 《国家队交易特征显著，短期指数仍 交易补缺预期，TMT 类题材仍需等待— —行业轮动周报 20250420》 - 2025.04.21 《小市值强势，动量风格占优——中 邮因子周报 20250420》 - 2025.04.21 《基本面与量价共振，如遇回调即是 买点——微盘股指数周报 20250420》 - 2025.04.21 《Meta LIama 4 开源，OpenAI 启动先 锋计划——AI 动态汇总 20250414》 - 2025.04.15 《融资盘被动 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [1] Core Views - The company, Jinhe Biological, reported a revenue of 2.371 billion yuan for 2024, representing a year-on-year growth of 9.04%, with a net profit attributable to shareholders of 100 million yuan, up 15.90% year-on-year. Excluding stock incentive expenses and goodwill impairment, the net profit was 157 million yuan, a significant increase of 57.59% year-on-year [4] - The veterinary pharmaceutical segment saw a revenue increase of 21.74% to 1.234 billion yuan in 2024, with a gross margin improvement of 7.4 percentage points to 40.17%. The sales volume of veterinary drugs increased by 21% in 2024 and 55.55% in Q1 2025, driven by new production capacity and increased application scenarios [5][6] - The company is the largest producer of chlortetracycline premix in the world, with a projected EPS of 0.30 yuan for 2025, corresponding to a PE ratio of only 21 times, indicating a favorable valuation [7] Company Overview - The latest closing price of the company's stock is 6.20 yuan, with a total market capitalization of 4.8 billion yuan and a circulating market capitalization of 4.6 billion yuan. The company has a total share capital of 772 million shares, with 745 million shares in circulation [3] - The company has a debt-to-asset ratio of 55.8% and a current PE ratio of 47.91 [3] Financial Performance - For 2025, the company expects a revenue of 2.726 billion yuan, representing a growth rate of 15%, and a net profit of 229 million yuan, with a growth rate of 128.52% [10] - The EBITDA for 2025 is projected to be 626.14 million yuan, with a significant increase in profitability metrics such as net profit margin and return on equity [13]

Investment Rating - The investment rating for the company is "Buy" and it is maintained [1] Core Insights - The company reported a revenue of 2.371 billion yuan in 2024, representing a year-on-year growth of 9.04%, with a net profit attributable to shareholders of 100 million yuan, up 15.90%. Excluding stock incentive costs and goodwill impairment, the net profit was 157 million yuan, a significant increase of 57.59% [4] - In Q1 2025, the company achieved a revenue of 625 million yuan, a year-on-year increase of 20.35%, with a net profit of 51 million yuan, up 13.23% [4] - The veterinary pharmaceutical segment saw a revenue increase of 21.74% to 1.234 billion yuan in 2024, with a gross margin improvement of 7.4 percentage points to 40.17% [5] - The company is the largest producer of chlortetracycline premix in the world, with a projected EPS of 0.30 yuan for 2025, corresponding to a PE ratio of only 21 times [7] Company Overview - The latest closing price of the company's stock is 6.20 yuan, with a total market capitalization of 4.8 billion yuan [3] - The company has a total share capital of 772 million shares, with 745 million shares in circulation [3] - The company has a debt-to-asset ratio of 55.8% and a current PE ratio of 47.91 [3] Financial Projections - The company expects revenues to grow to 2.726 billion yuan in 2025, with a net profit of 229 million yuan, reflecting a growth rate of 128.52% [10] - The projected EPS for 2026 and 2027 are 0.39 yuan and 0.47 yuan, respectively, with corresponding PE ratios decreasing to 15.89 and 13.41 [10][13]